Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

• Principais autores: Chun Liu (Autor), Pier Giorgio Cojutti (Autor), Maddalena Giannella (Autor), Marcello Roberto (Autor), Beatrice Casadei (Autor), Gianluca Cristiano (Autor), Cristina Papayannidis (Autor), Nicola Vianelli (Autor), Pier Luigi Zinzani (Autor), Pierluigi Viale (Autor), Francesca Bonifazi (Autor), Federico Pea (Autor)
• Formato: Livro
• Publicado em: MDPI AG, 2023-03-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Chimeric antigen receptor (CAR) T-cell therapy is a promising approach for some relapse/refractory hematological B-cell malignancies; however, in most patients, cytokine release syndrome (CRS) may occur. CRS is associated with acute kidney injury (AKI) that may affect the pharmacokinetics of some be...